These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36151052)

  • 1. Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment.
    Javitt DC
    Annu Rev Pharmacol Toxicol; 2023 Jan; 63():119-141. PubMed ID: 36151052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia.
    Kantrowitz JT
    Schizophr Res; 2019 May; 207():70-79. PubMed ID: 29459050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.
    Kantrowitz JT; Epstein ML; Beggel O; Rohrig S; Lehrfeld JM; Revheim N; Lehrfeld NP; Reep J; Parker E; Silipo G; Ahissar M; Javitt DC
    Brain; 2016 Dec; 139(Pt 12):3281-3295. PubMed ID: 27913408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early auditory processing dysfunction in schizophrenia: Mechanisms and implications.
    Dondé C; Kantrowitz JT; Medalia A; Saperstein AM; Balla A; Sehatpour P; Martinez A; O'Connell MN; Javitt DC
    Neurosci Biobehav Rev; 2023 May; 148():105098. PubMed ID: 36796472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.
    Kantrowitz JT; Swerdlow NR; Dunn W; Vinogradov S
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2018 Jul; 3(7):581-590. PubMed ID: 29656951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia.
    Javitt DC; Zukin SR; Heresco-Levy U; Umbricht D
    Schizophr Bull; 2012 Sep; 38(5):958-66. PubMed ID: 22987851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.
    Lee M; Balla A; Sershen H; Sehatpour P; Lakatos P; Javitt DC
    Neuropsychopharmacology; 2018 Feb; 43(3):571-582. PubMed ID: 28816240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hierarchical Pathways from Sensory Processing to Cognitive, Clinical, and Functional Impairments in Schizophrenia.
    Koshiyama D; Thomas ML; Miyakoshi M; Joshi YB; Molina JL; Tanaka-Koshiyama K; Sprock J; Braff DL; Swerdlow NR; Light GA
    Schizophr Bull; 2021 Mar; 47(2):373-385. PubMed ID: 32856089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?
    Kantrowitz JT; Javitt DC
    Brain Res Bull; 2010 Sep; 83(3-4):108-21. PubMed ID: 20417696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia.
    Amitai N; Markou A
    Biol Psychiatry; 2010 Jul; 68(1):5-16. PubMed ID: 20488434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis.
    Gilmour G; Dix S; Fellini L; Gastambide F; Plath N; Steckler T; Talpos J; Tricklebank M
    Neuropharmacology; 2012 Mar; 62(3):1401-12. PubMed ID: 21420987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Augmenting N-Methyl-D-Aspartate Receptor Signaling on Working Memory and Experience-Dependent Plasticity in Schizophrenia: An Exploratory Study Using Acute d-cycloserine.
    Forsyth JK; Bachman P; Mathalon DH; Roach BJ; Ye E; Asarnow RF
    Schizophr Bull; 2017 Sep; 43(5):1123-1133. PubMed ID: 28338977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurophysiological Effects of Bitopertin in Schizophrenia.
    Kantrowitz JT; Nolan KA; Epstein ML; Lehrfeld N; Shope C; Petkova E; Javitt DC
    J Clin Psychopharmacol; 2017 Aug; 37(4):447-451. PubMed ID: 28590364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between dopamine transporter and N-methyl-d-aspartate receptor-related amino acids on cognitive impairments in schizophrenia.
    Yang KC; Chen YY; Liu MN; Yang BH; Chou YH
    Schizophr Res; 2022 Oct; 248():263-270. PubMed ID: 36115191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.
    Hamilton HK; D'Souza DC; Ford JM; Roach BJ; Kort NS; Ahn KH; Bhakta S; Ranganathan M; Mathalon DH
    Schizophr Res; 2018 Jan; 191():87-94. PubMed ID: 28711472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum anti-NMDA receptor antibody levels in first-episode patients with schizophrenia.
    Tong J; Huang J; Luo X; Chen S; Cui Y; An H; Xiu M; Tan S; Wang Z; Yuan Y; Zhang J; Yang F; Li CR; Hong LE; Tan Y
    Brain Behav Immun; 2019 Oct; 81():213-219. PubMed ID: 31201848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute NMDA receptor antagonism impairs working memory performance but not attention in rats-Implications for the NMDAr hypofunction theory of schizophrenia.
    Lee J; van den Buuse M; Nithianantharajah J; Jones NC
    Behav Neurosci; 2020 Aug; 134(4):323-331. PubMed ID: 32658524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model.
    Haaf M; Leicht G; Curic S; Mulert C
    Curr Pharm Biotechnol; 2018; 19(4):293-307. PubMed ID: 29929462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDE Inhibitors for the Treatment of Schizophrenia.
    Snyder GL; Vanover KE
    Adv Neurobiol; 2017; 17():385-409. PubMed ID: 28956340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.